Decreased serum apolipoprotein A1 levels are associated with poor survival and systemic inflammatory response in colorectal cancer

Recent studies have reported of an association between high serum apolipoprotein A1 (APOA1) levels and favorable prognosis in several malignancies, while the significance of apolipoprotein B (APOB) in cancer is less well-known. In this study, we analyzed the correlation between serum APOA1 and APOB levels, and APOB/APOA1 ratio, and their associations with clinicopathologic parameters, the levels of twenty systemic inflammatory markers, and survival in 144 colorectal cancer (CRC) patients. We demonstrated that low serum APOA1 levels associated with advanced T-class and TNM-stage but low serum APOB levels did not significantly correlate with tumor characteristics. Serum APOA1 levels showed strong negative correlation with the markers of systemic inflammation including serum CRP and interleukin (IL)-8 levels and blood neutrophil count, whereas high serum APOB levels associated with high serum CCL2 levels. High APOA1 and APOB levels and low APOB/APOA1 ratio associated with improved cancer specific and overall survival. APOA1 had independent prognostic value in Cox regression analysis. In conclusion, low serum APOA1 levels are associated with advanced stage and systemic inflammation, while serum APOB does not significantly correlate with tumor stage. Serum APOA1 represents a promising additional prognostic parameter in CRC.

[1]  Michael J. Thomas,et al.  Activation of lecithin: cholesterol acyltransferase by HDL ApoA-I central helices , 2009, Clinical lipidology.

[2]  T. Pihlajaniemi,et al.  Serum endostatin levels are elevated in colorectal cancer and correlate with invasion and systemic inflammatory markers , 2014, British Journal of Cancer.

[3]  K. Feingold,et al.  The acute phase response inhibits reverse cholesterol transport1 , 2010, Journal of Lipid Research.

[4]  H. Minuk,et al.  Metabolic syndrome. , 2005, Journal of insurance medicine.

[5]  Qing Liu,et al.  Serum apolipoprotein A-I is a novel prognostic indicator for non-metastatic nasopharyngeal carcinoma , 2015, Oncotarget.

[6]  T. Salo,et al.  Serum MMP‐8 levels increase in colorectal cancer and correlate with disease course and inflammatory properties of primary tumors , 2012, International journal of cancer.

[7]  R. Bloigu,et al.  Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma , 2012, British Journal of Cancer.

[8]  R. Karas,et al.  Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. , 2010, Journal of the American College of Cardiology.

[9]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[10]  J. Väyrynen,et al.  Clinical impact and network of determinants of tumour necrosis in colorectal cancer , 2016, British Journal of Cancer.

[11]  K. McGlynn,et al.  Risk of cancer in a large cohort of U.S. veterans with diabetes , 2011, International journal of cancer.

[12]  R. Hayes,et al.  Prediagnostic Total and High-Density Lipoprotein Cholesterol and Risk of Cancer , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[13]  Sun Woo Kim,et al.  Association of lipid and lipoprotein profiles with future development of type 2 diabetes in nondiabetic Korean subjects: a 4-year retrospective, longitudinal study. , 2011, The Journal of clinical endocrinology and metabolism.

[14]  L. Lind,et al.  Evaluation of a scoring scheme, including proinsulin and the apolipoprotein B/apolipoprotein A1 ratio, for the risk of acute coronary events in middle-aged men: Uppsala Longitudinal Study of Adult Men (ULSAM). , 2005, American heart journal.

[15]  E. Bartoli,et al.  ApoB/apoA-I ratio is better than LDL-C in detecting cardiovascular risk. , 2011, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[16]  Jos H Beijnen,et al.  Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. , 2006, World journal of gastroenterology.

[17]  R. Hardy,et al.  The metabolic syndrome: A high-risk state for cancer? , 2006, The American journal of pathology.

[18]  A. Nègre-Salvayre,et al.  Structural modifications of HDL and functional consequences. , 2006, Atherosclerosis.

[19]  K. Tasanen,et al.  Collagen XVII expression correlates with the invasion and metastasis of colorectal cancer. , 2015, Human pathology.

[20]  F. Bosman,et al.  WHO Classification of Tumours of the Digestive System , 2010 .

[21]  D R Jacobs,et al.  High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. , 1990, American journal of epidemiology.

[22]  N. Wong,et al.  Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF α and IL-1β , 2003 .

[23]  Juan Li,et al.  The association between serum lipids and colorectal neoplasm: a systemic review and meta-analysis , 2015, Public Health Nutrition.

[24]  Qifu Li,et al.  The relationship between high-sensitivity C-reactive protein and ApoB, ApoB/ApoA1 ratio in general population of China , 2012, Endocrine.

[25]  E. Riboli,et al.  Biomarker patterns of inflammatory and metabolic pathways are associated with risk of colorectal cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC) , 2014, European Journal of Epidemiology.

[26]  J. Ryoo,et al.  Association of apolipoprotein B and incidence of metabolic syndrome in Korean men: a 5-years' follow-up study. , 2013, Atherosclerosis.

[27]  D. McMillan,et al.  Circulating IL-6 concentrations link tumour necrosis and systemic and local inflammatory responses in patients undergoing resection for colorectal cancer , 2013, British Journal of Cancer.

[28]  Grant Morahan,et al.  The Affymetrix DMET Plus Platform Reveals Unique Distribution of ADME-Related Variants in Ethnic Arabs , 2015, Disease markers.

[29]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[30]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[31]  D. McMillan.  The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. , 2013, Cancer treatment reviews.

[32]  W. Boden.  High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial. , 2000, The American journal of cardiology.

[33]  J. Borg,et al.  Quantitative proteomic analysis exploring progression of colorectal cancer: Modulation of the serpin family. , 2016, Journal of proteomics.

[34]  N. Wong,et al.  Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF alpha and IL-1beta. , 2003, Biochimica et biophysica acta.

[35]  G. Paumgartner,et al.  Decreased High-Density Lipoprotein Cholesterol and Increased Low-Density Cholesterol Levels in Patients with Colorectal Adenomas , 1993, Annals of Internal Medicine.

[36]  A. Nicolaides,et al.  ApoB/ApoA1 ratio and subclinical atherosclerosis. , 2008, International angiology : a journal of the International Union of Angiology.

[37]  R. Bloigu,et al.  Reply: Comment on 'Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma' , 2013, British Journal of Cancer.

[38]  A. Rosengren,et al.  Comparison of Apolipoprotein (apoB/apoA-I) and Lipoprotein (Total Cholesterol/HDL) Ratio Determinants. Focus on Obesity, Diet and Alcohol Intake , 2012, PloS one.

[39]  R. Weinberg,et al.  The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis , 2014, Nature Cell Biology.

[40]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[41]  M. Zamanian-Daryoush,et al.  Apolipoprotein A-I and Cancer , 2015, Front. Pharmacol..

[42]  T. Lüscher,et al.  Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease , 2012, EMBO molecular medicine.

[43]  Pasi Soininen,et al.  Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. , 2015, Circulation. Cardiovascular genetics.

[44]  W. Zheng,et al.  Plasma lipid levels and colorectal adenoma risk , 2015, Cancer Causes & Control.

[45]  F. Clavel-Chapelon,et al.  Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition , 2011, Gut.

[46]  R. Rabasa-Lhoret,et al.  Apolipoprotein B: a predictor of inflammatory status in postmenopausal overweight and obese women , 2006, Diabetologia.

[47]  R. Bloigu,et al.  The relationships between serum cytokine levels and tumor infiltrating immune cells and their clinical significance in colorectal cancer , 2016, International journal of cancer.

[48]  J. Odland,et al.  The Apolipoprotein B/Apolipoprotein A-I Ratio as a Potential Marker of Plasma Atherogenicity , 2015, Disease markers.

[49]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.

[50]  Olle Melander,et al.  Apolipoproteins, lipids and risk of cancer , 2016, International journal of cancer.

[51]  B. Krušlin,et al.  The Correlation Between the Tumor Necrosis and Renal Artery Changes in Renal Cell Carcinoma , 2006, International journal of surgical pathology.

[52]  S. Grundy,et al.  The metabolic syndrome. , 2008, Endocrine reviews.

[53]  A. Tall,et al.  Regulation and Mechanisms of ATP-Binding Cassette Transporter A1-Mediated Cellular Cholesterol Efflux , 2003, Arteriosclerosis, thrombosis, and vascular biology.